RCT to Investigate if Prophylactic Antibiotics Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH1)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To assess whether a period of prophylactic penicillin after an episode of cellulitis of the leg reduces the risk of repeat episodes. Participants are randomised to receive 12 months of prophylaxis (penicillin VK 250mg b.d. or placebo). The PATCH I study will recruit only patients with recurrent disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Cellulitis/Erysipelas of the Leg |
Drug: Penicillin VK Other: placebo |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Randomised Controlled Trial to Investigate Whether Prophylactic Antibiotics Can Prevent Further Episodes of Cellulitis (Erysipelas) of the Leg (PATCH I) |
- The primary outcome is time to next episode of cellulitis [ Time Frame: variable ] [ Designated as safety issue: No ]
- Secondary outcomes include: i) the proportion of participants with repeat episodes of cellulitis; ii) proportion of participants with oedema and/or ulceration; iii) cost-effectiveness; iv) predictors of response (multiple regression model). [ Time Frame: variable ] [ Designated as safety issue: No ]
| Enrollment: | 274 |
| Study Start Date: | July 2006 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Penicillin VK 250 mg b.d.
|
Drug: Penicillin VK
Biconcave tablet 250mg oral, b.d.
|
|
Placebo Comparator: 2
placebo tablet b.d.
|
Other: placebo
biconcave tablet matching active comparator as much as possible in size and shape
|
Detailed Description:
Cellulitis of the leg is an common, acute, painful and potentially serious infection of the skin and subcutaneous tissue. It currently accounts for 2-3% of UK hospital admissions. The average length of in-patient stay is 9 days (Hospital Episode Statistics, Department of Health (UK), 2002-2003) and 25-50% of treated patients suffer further episodes and other morbidity, such as oedema and ulceration.
Cellulitis of the lower leg is usually due to streptococcal infection that has entered into the body via a relatively subtle portal, such as toeweb fissures. Penicillin is the most useful of the commonly used oral antibiotics against streptococci, although other agents such as flucloxacillin are often used if staphylococcal infection is a clinical possibility.
There are numerous risk factors for cellulitis of the lower leg and recurrent disease is one the biggest problems.
Existing evidence for the use of prophylactic antibiotics to prevent further episodes is very limited. Two small randomised controlled trials (RCTs) hint at possible benefit, but these studies are very small (16 and 40 participants respectively). Despite this, many physicians routinely use prophylactic antibiotics for recurrent cellulitis, although opinions on the value of such practice is firmly divided.
This study will recruit over a 12-24 month period participants who have completed the therapy for the current episode of cellulitis. Participants will be followed up for up to 24 months with telephone calls at 10 days, 3 months, 6 months, 9 months and 12 months and then every 6 months after completing the intervention. A diary will also be provided as an "aid memoir" to phone calls and to note missed tablets and recurrence of cellulitis.
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of cellulitis of either leg AND a history of at least one previous episode of cellulitis of either leg within the three
Exclusion Criteria:
Any doubt about the certainty of the diagnosis of either the index episode or the previous episode (if applicable), will be grounds for exclusion. Additionally, patients with any of the following will be excluded:
- Taken antibiotic prophylaxis (defined as more than 3 months usage) for the prevention of cellulitis within 6 months prior to index episode.
- A time lapse of longer than 12 weeks since the start of treatment for the index episode to the date of potential randomisation into the trial.
- Known allergy to penicillin.
- Preceding leg ulceration, surgery or penetrating trauma, as these cases are more likely to be caused by staphylococcal infection. (NB: this does not exclude patients with toeweb maceration/tinea pedis or other minor/blunt wounds).
Treating physician or principal investigator unwilling to randomise patient. This includes, but is not limited to:
- The treating physician and/or patient feels that prophylactic antibiotics are not in the patient's best interests and therefore entry to this study would be inappropriate.
- The treating physician and/or patient feels it would not be ethical or appropriate for the patient to receive placebo and so they are not willing/able to accept randomisation
- Concomitant medication that would mean that long-term penicillin is inappropriate
- Diagnostic uncertainty
- Gastrointestinal disease causing persistent diarrhoea or vomiting severe enough to affect the absorption of the phenoxymethylpenicillin.
- Allergic diathesis or severe bronchial asthma severe enough to preclude the use of phenoxymethylpenicillin.
- Confounding concurrent disease (e.g. DVT).
- No access to a telephone.
- Aged less than 16 years.
- Unable to give informed consent.
- Already taking part in a research study.
Contacts and Locations| Ireland | |
| South Infirmary-Victoria University Hospital | |
| Cork, Ireland | |
| United Kingdom | |
| Queens Medical Centre | |
| Nottingham, Nottinghamshire, United Kingdom, NG7 2UH | |
| Aberdeen Royal Infirmary | |
| Aberdeen, United Kingdom, AB25 2ZN | |
| Amersham Hospital | |
| Amersham, United Kingdom, HP7 0JD | |
| Brighton General Hospital | |
| Brighton, United Kingdom, BN2 3EW | |
| Bristol Royal Infirmary | |
| Bristol, United Kingdom, BS2 8HW | |
| Cumberland Infirmary | |
| Carlisle, United Kingdom, CA2 7HY | |
| Derbyshire Royal Infirmary | |
| Derby, United Kingdom, DE1 2QY | |
| University Hospital of North Durham | |
| Durham, United Kingdom, DE1 5TW | |
| Gloucestershire Royal Infirmary | |
| Gloucester, United Kingdom, GL1 3NN | |
| James Paget University Hospital | |
| Great Yarmouth, United Kingdom, NR31 6LA | |
| Princess Royal Hospital | |
| Hull, United Kingdom, HU8 9HE | |
| Ipswich Hospital | |
| Ipswich, United Kingdom, IP4 5HD | |
| Queen Elizabeth Hospital | |
| King's Lynn, United Kingdom, PE30 4ET | |
| Leicester Royal Infirmary | |
| Leicester, United Kingdom, LE1 5WW | |
| Broadgreen Hospital | |
| Liverpool, United Kingdom, L14 3LB | |
| Altnagelvin Area Hospital | |
| Londonderry, United Kingdom, BT47 6SB | |
| Royal Victoria Infirmary | |
| Newcastle upon Tyne, United Kingdom, NE1 4LP | |
| Norfolk and Norwich University Hospital | |
| Norwich, United Kingdom, NR4 7UY | |
| Royal Berkshire Hospital | |
| Reading, United Kingdom, RG1 5AN | |
| Hope Hospital | |
| Salford, United Kingdom, M6 8HD | |
| King's Mill Hospital | |
| Sutton in Ashfield, United Kingdom, NG17 4JL | |
| Singleton Hospital | |
| Swansea, United Kingdom, SA2 8QA | |
| Watford General Hospital | |
| Watford, United Kingdom, WD1 8HB | |
| York Hospital | |
| York, United Kingdom, YO31 8HR | |
| Study Director: | Hywel Williams, Professor | University of Nottingham |
More Information
Additional Information:
No publications provided
| Responsible Party: | University of Nottingham |
| ClinicalTrials.gov Identifier: | NCT00552799 History of Changes |
| Other Study ID Numbers: | 06002, ISRCTN34716921, EudraCT No. 2006-000381-36 |
| Study First Received: | November 1, 2007 |
| Last Updated: | July 23, 2012 |
| Health Authority: | United Kingdom: Research Ethics Committee United Kingdom: Medicines and Healthcare Products Regulatory Agency Ireland: Irish Medicines Board Ireland: Medical Ethics Research Committee |
Keywords provided by University of Nottingham:
|
cellulitis lymphoedema penicillin clinical trial |
Additional relevant MeSH terms:
|
Cellulitis Erysipelas Skin Diseases, Infectious Infection Suppuration Connective Tissue Diseases Inflammation Pathologic Processes Streptococcal Infections |
Gram-Positive Bacterial Infections Bacterial Infections Skin Diseases, Bacterial Skin Diseases Anti-Bacterial Agents Penicillin V Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013